{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:58:40Z","timestamp":1787003920939,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T00:00:00Z","timestamp":1148256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T00:00:00Z","timestamp":1148256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2006,7,1]]},"DOI":"10.1038\/sj.bmt.1705398","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T06:37:38Z","timestamp":1148279858000},"page":"47-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"38","author":[{"given":"B","family":"Sirohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R L","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H G","family":"Prentice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Koblinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,5,22]]},"reference":[{"key":"BF1705398_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1086\/513764","volume":"25","author":"WT Hughes","year":"1997","unstructured":"Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551\u2013573.","journal-title":"Clin Infect Dis"},{"key":"BF1705398_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jac\/40.6.779","volume":"40","author":"AG Prentice","year":"1997","unstructured":"Prentice AG, Barnes RA, Rogers TRF, Cohen J, Denning DW, Evans EGV et al. Therapy of deep fungal infection in hematological malignancy. J Antimicrob Chemother 1997; 40: 779\u2013788.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"BF1705398_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1470-9465.2004.00838.x","volume":"10","author":"JP Donnelly","year":"2004","unstructured":"Donnelly JP, De Pauw BE . Voriconazole \u2013 a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004; 10 (Suppl 1): 107\u2013117.","journal-title":"Clin Microbiol Infect"},{"key":"BF1705398_CR4","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/cncr.10610","volume":"94","author":"EJ Bow","year":"2002","unstructured":"Bow EJ, Laverdi\u00e8re M, Lussier N, Rotstein C, Cheang MS, Ioannou S . Antifungal prophylaxis for severely neutropenic chemotherapy patients: a meta-analysis of randomized controlled trials. Cancer 2002; 94: 3230\u20133246.","journal-title":"Cancer"},{"key":"BF1705398_CR5","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","volume":"15","author":"A Glasmacher","year":"2003","unstructured":"Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J Clin Oncol 2003; 15: 4615\u20134626.","journal-title":"J Clin Oncol"},{"key":"BF1705398_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"25","author":"J Mora-Duarte","year":"2002","unstructured":"Mora-Duarte J, Betts R, Rotstein C, Lopes Colombo A, Thompson-Moya L, Smietana J . Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 25: 2020\u20132029.","journal-title":"N Engl J Med"},{"key":"BF1705398_CR7","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1086\/423381","volume":"39","author":"J Maertens","year":"2004","unstructured":"Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563\u20131571.","journal-title":"Clin Infect Dis"},{"key":"BF1705398_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMoa040446","volume":"30","author":"TJ Walsh","year":"2004","unstructured":"Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 30: 1391\u20131402.","journal-title":"N Engl J Med"},{"key":"BF1705398_CR9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1128\/AAC.49.4.1331-1336.2005","volume":"49","author":"J Hiemenz","year":"2005","unstructured":"Hiemenz J, Gagnoni P, Simpson D, Devine S, Chao N, Keirns J et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for the prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331\u20131336.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1705398_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00944177","volume":"10","author":"S Green","year":"1992","unstructured":"Green S, Weiss GR . Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239\u2013253.","journal-title":"Invest New Drugs"},{"key":"BF1705398_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/clinids\/18.4.525","volume":"18","author":"HFL Guiot","year":"1994","unstructured":"Guiot HFL, Fibbe WL, van't Wout JW . Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empiric therapy and prophylaxis. Clin Infect Dis 1994; 18: 525\u2013532.","journal-title":"Clin Infect Dis"},{"key":"BF1705398_CR12","first-page":"405","volume":"2","author":"AH Groll","year":"2000","unstructured":"Groll AH, Walsh TJ . FK463, Fujisawa Pharmaceutical Co Ltd. Curr Opin Anti-infect Invest Drugs 2000; 2: 405\u2013412.","journal-title":"Curr Opin Anti-infect Invest Drugs"},{"key":"BF1705398_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1128\/AAC.44.1.57-62.2000","volume":"44","author":"S Tawara","year":"2000","unstructured":"Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1705398_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1128\/AAC.44.3.614-618.2000","volume":"44","author":"F Ikeda","year":"2000","unstructured":"Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E, Tawara S et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614\u2013618.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1705398_CR15","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1128\/AAC.44.6.1728-1730.2000","volume":"44","author":"S Maesaki","year":"2000","unstructured":"Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S . Efficacy of FK463, a (1,3)-\u00df-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 2000; 44: 1728\u20131730.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1705398_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1128\/AAC.44.3.619-621.2000","volume":"44","author":"S Matsumoto","year":"2000","unstructured":"Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000; 44: 619\u2013621.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1705398_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1086\/423377","volume":"39","author":"N de Wet","year":"2004","unstructured":"de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842\u2013849.","journal-title":"Clin Infect Dis"},{"key":"BF1705398_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1177\/0091270005278601","volume":"45","author":"MF Herbert","year":"2005","unstructured":"Herbert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954\u2013960.","journal-title":"J Clin Pharmacol"},{"key":"BF1705398_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/0091270005279274","volume":"45","author":"MF Herbert","year":"2005","unstructured":"Herbert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 1018\u20131024.","journal-title":"J Clin Pharmacol"},{"key":"BF1705398_CR20","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/422312","volume":"39","author":"JA van Burik","year":"2004","unstructured":"van Burik JA, Ratanatharathorn V, Stepan DE, Millr CB, Lipton JH, Vesole DH et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407\u20131416.","journal-title":"Clin Infect Dis"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705398","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T20:09:26Z","timestamp":1648066166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7,1]]}},"alternative-id":["BF1705398"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705398","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,22]]},"assertion":[{"value":"1 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}